Purpose: Elevation of blood homocysteine (Hcy) level (hyperhomocysteinemia) is a risk factor for cardiovascular disorders and is closely associated with endothelial dysfunction. The present study aims to investigate the protective effect and underlying mechanism of nanoscale selenium (Nano-Se) in Hcy-mediated vascular endothelial cell dysfunction in vitro and in vivo. Materials and Methods: By incubating vascular endothelial cells with exogenous Hcy and generating hyperhomocysteinemic rat model, the effects of Nano-Se on hyperhomocysteinemia-mediated endothelial dysfunction and its essential mechanisms were investigated. Results: Nano-Se inhibited Hcy-induced mitochondrial oxidative damage and apoptosis by preventing the downregulation of glutathione peroxidase enzyme 1 and 4 (GPX1, GPX4) in the vascular endothelial cells, thus effectively prevented the vascular damage in vitro and in vivo in the hyperhomocysteinemic rats. Nano-Se possessed similar protective effects but lower toxicity against Hcy in vascular endothelial cells when compared with other forms of Se. Conclusion: The application of Nano-Se could serve as a novel promising strategy against Hcy-mediated vascular dysfunction with reduced risk of Se toxicity.
High levels of homocysteine (Hcy) associated with cardiovascular events are accompanied by increased copper (Cu) concentrations in the blood. Hcy has been shown to promote endothelial dysfunction, whereas the effect of Hcy on cardiomyocytes and the role of Cu in the pathogenesis remain less understood. In the present study, it is demonstrated that the combination of Hcy and Cu2+-induced apoptosis and autosis of cardiomyocytes simultaneously, and thus led to cardiac dysfunction in hyperhomocysteinemic rats. These effects were associated with p22phoxactivation and NADPH oxidase (NOX)-mediated p62 upregulation. Inhibition of the expression of p22phoxor p62 in cardiomyocytes significantly attenuated Hcy and Cu2+-mediated reactive oxygen species (ROS) generation and cell death. Furthermore, interrupting the NOX–p62 axis prevented diastolic dysfunction in hyperhomocysteinemic rats (HcyR). These findings establish that the induction of apoptosis and autosis of cardiomyocytes through stimulating the NOX–p62-signaling pathway constitutes a novel mechanism of Hcy and Cu-induced cardiac dysfunction.
Homocysteine (Hcy) is not only associated with the development of chronic cardiovascular diseases like atherosclerosis, but may also participate in the acute cardiovascular events. However, the exact mechanism of the latter remains elusive. The present study aims to further investigate the mechanism of cardiac microvascular endothelial cells (CMECs) death after I/R induction in the presence of Hcy and explore new therapeutic strategies. By generating the hypoxia/reoxygenation (H/R) human cardiac microvascular endothelial cell (HCMEC) model and the I/R models in rats with hyperhomocysteinemia (HHcy), the mechanisms of endothelial cell injury associated with HHcy were investigated. We demonstrated that ONOO−, generated by the combination of Hcy and Cu2+ during I/R, induces ER stress and the subsequent ER-mitochondria Ca2+ transfer via IP3R-mediated Ca2+ release in CMECs. The cytosolic/mitochondrial Ca2+ oscillations and mitochondrial Ca2+ overload promote mROS generation, provoke LMP, and ultimately drive CMEC necroptosis. Our study further demonstrates the IP3R inhibitor 2-APB (5 mg/kg) significantly reduced infarct size by 29.14%, and improved cardiac function in HHcy rats (HHcyR), as evidenced by increased LVEF (35.71% → 55.32%), elevated LVFS (31.44% → 48.54%), and reduced LVEDd (6.98 mm → 5.80 mm). Altogether, our results reveal the pathological role of Hcy in acute cardiovascular events. We show that HHcy aggravates cardiac microvascular I/R injury via ONOO−-driven ER stress that triggers IP3R-mediated Ca2+ mis-handling, culminating in mitochondrial dysfunction and necroptosis. These data identify IP3R-dependent Ca2+ transfer as a tractable pathway for HHcy-complicated reperfusion injury.
Background Chromatin modified protein 4C (CHMP4C) is a charged polyvesicular protein (CHMP) that is involved in the composition of the endosomal sorting complex (ESCRT-III) required for transport III and promotes the necessary separation of daughter cells. CHMP4C involved in a wide variety of tumor progress, such as prostate cancer, cervical cancer and lung squamous cell carcinoma. However, the value of CHMP4C in lung adenocarcinoma has not been explored. Methods RNA-seq data and lung adenocarcinoma clinical information and corresponding pan-cancer were extracted from The Cancer Genome Atlas (TCGA) database to analyze CHMP4C expression and survival prognosis. The differential expression of CHMP4C was analyzed using the Human Protein Atlas (HPA) database. Clinical samples were collected to verify the differential expression of CHMP4C between lung adenocarcinoma and normal lung tissues via immunohistochemical (IHC) staining, qRT‒PCR and Western blotting. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses of CHMP4C-related genes were performed. The correlation between CHMP4C and chemosensitivity was analyzed in the TCGA database. Then, qRT‒PCR, western blotting, transwell assays, cell proliferation assays, colony formation assays, wound healing assays, and cell cycle analysis were used to verify the possible regulatory mechanism involved. Molecular docking was used to predict small molecule compounds with potential roles in the treatment of lung adenocarcinoma. Results TIMER2.0 database analysis revealed that CHMP4C was differentially expressed in different tumors.Compared with that in healthy lung tissue, CHMP4C was significantly upregulated in lung adenocarcinoma tissue, and subsequent in vitro survival analysis revealed that CHMP4C expression has significant clinical prognostic value in lung adenocarcinoma. Enrichment analysis revealed that CHMP4C was mainly related to cell proliferation, cell migration, and the PI3K-Akt signaling pathway, etc. Overexpression of CHMP4C was associated with sensitivity to chemotherapy. Knocking down CHMP4C can significantly inhibit the proliferation, migration and invasion of lung adenocarcinoma cells and prolong the G0/G1 phase of the cell cycle. Molecular docking predicts 10 key drugs that may be used for the treatment of lung adenocarcinoma. Conclusions CHMP4C is highly expressed in a variety of tumors. We demonstrated that CHMP4C expression may be associated with the occurrence, development, prognosis and chemotherapy sensitivity in patients with lung adenocarcinoma. These findings may open up new research directions and development opportunities for the treatment of lung adenocarcinoma.